Global Epigenetics Market, By Product (Enzymes, Instruments and Consumables, Kits, Reagents), Application (Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Others), Technology (DNA Methylation, Histone Methylation, Others), End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations (CROs)) – Industry Trends and Forecast to 2030.
Epigenetics Market Analysis and Size
Epigenetic mechanisms are being linked to an increasing number of chronic diseases and disorders, such as cardiovascular disease, autoimmune disease, and neurodegenerative disorders, and environmental factors and nutritional imbalance, all of which have a significant impact on epigenetic processes such as DNA methylation, histone modification, and non-coding RNA.
Data Bridge Market Research analyzes that the global epigenetics market which was USD 13.17 billion in 2022, would rocket up to USD 57.40 billion by 2030, and is expected to undergo a CAGR of 20.20% during the forecast period. The “Enzymes” segment is expected to dominate the product segment of the market owing to the rise in cancer prevalence rate worldwide.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Epigenetics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Enzymes, Instruments and Consumables, Kits, Reagents), Application (Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Others), Technology (DNA Methylation, Histone Methylation, Others), End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations (CROs))
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Illumina, Inc. (U.S.), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd. (Japan), Novartis AG (Switzerland), Abcam plc (U.K.), Diagenode s.a. (U.S.), Active Motif, Inc. (U.S.), Zymo Research Corporation. (U.S.), Thermo Fisher Scientific (U.S.), Cellcentric (Germany), Syndax (U.S.), New England Biolabs (U.S.), Epizyme, Inc. (U.S.), Domainex (U.K.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), AsisChem Inc. (U.S.), Enzo Life Sciences, Inc. (U.S.), EpiGentek Group Inc. (U.S.), BioVision Inc. (U.S.), Bio-Techne. (U.S.), Promega Corporation (U.S.), GeneTex, Inc. (U.S.), and Pacific Biosciences of California, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Epigenetics is a branch of genetics concerned with the study of cellular and physiological trait variations caused by environmental or ecological factors that turn genes on and off and influence the cellular ability to read genes without being affected by genotype changes. It causes changes in an organism's phenotype rather than genotype, with the underlying DNA or RNA sequence remaining constant.
Global Epigenetics Market Dynamics
Drivers
- Increasing Cancer Research
Epigenetics plays a crucial role in the development and progression of cancer. There is a growing emphasis on understanding the epigenetic modifications associated with different types of cancer as cancer research continues to advance. This drives demand for epigenetic analysis tools and technologies, including DNA methylation and histone modification assays.
- Rising Prevalence of Chronic Diseases
Chronic diseases such as diabetes, cardiovascular diseases, and neurological disorders have been linked to epigenetic changes. With the increasing global burden of these diseases, there is a growing need for epigenetic research to identify potential biomarkers and therapeutic targets, which contributes to market growth.
- Personalized Medicine and Drug Development
Epigenetic profiling allows for personalized medicine approaches, where treatments and therapies can be tailored to an individual's unique epigenetic profile. This has gained importance in the development of targeted therapies and drug discovery, thereby driving the adoption of epigenetic technologies by pharmaceutical and biotechnology companies.
- Technological Advancements
Ongoing advancements in epigenetic research tools and technologies, including next-generation sequencing, DNA methylation arrays, and epigenome editing techniques, have made epigenetic analysis more accessible and cost-effective. These technological innovations have expanded the capabilities of researchers and healthcare professionals, further fueling the market growth.
Opportunities
- Precision Medicine Advancements
Epigenetics has the potential to revolutionize the field of precision medicine. There is a significant opportunity to develop personalized treatment strategies based on a patient's epigenetic profile as our understanding of epigenetic modifications and their role in disease increases. This could lead to more effective and targeted therapies for various diseases, including cancer and neurological disorders.
- Biomarker Discovery
Epigenetic markers can serve as valuable biomarkers for various diseases. Identifying and validating epigenetic biomarkers for early disease detection, disease prognosis, and treatment response monitoring can create new opportunities for diagnostic and prognostic tests. These tests can aid in early intervention and personalized patient care.
Restraints
- Limited Understanding of Epigenetic Mechanisms
The complexity of epigenetic mechanisms and their role in various diseases is not yet fully understood. This limited understanding can hinder the development of targeted therapies and diagnostics, and the identification of reliable epigenetic biomarkers.
- High Costs of Tools
Many epigenetic analysis techniques and tools can be expensive, which can make them less accessible to researchers and healthcare providers with limited budgets. The high cost of equipment, reagents, and data analysis tools can be a significant barrier to entry and adoption.
Challenges
- Data Complexity and Interpretation
Epigenetic data is inherently complex, often involving large datasets with numerous layers of information. Analyzing and interpreting this data can be challenging, requiring advanced bioinformatics and computational tools. Researchers and clinicians need to overcome these challenges to translate epigenetic findings into actionable insights.
- Standardization and Quality Control
Ensuring the quality and consistency of epigenetic data and assays is crucial for reliable research and clinical applications. Standardization of epigenetic protocols, assays, and data analysis procedures is a challenge, as variations in techniques and platforms can lead to discrepancies and difficulties in comparing results across studies.
The global epigenetics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on this market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Development
- In February 2022, Zenith Epigenetics Ltd. reported the dosing of the first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer
- In February 2022, Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, entered a partnership with Dovetail Genomics to demonstrate the value and performance of Dovetail’s proximity ligation-based-based next-generation sequencing (NGS) library prep solutions on Element’s AVITI System
Global Epigenetics Market Scope
The global epigenetics market is segmented on the basis of product, application, technology, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Enzymes
- DNA-modifying enzymes
- Protein-modifying enzymes
- RNA-modifying enzymes
- Instruments and Consumables
- Next-generation sequencers
- qPCR, mass spectrometers
- Sonicators
- Others
- Kits
- Bisulfite conversion kits
- ChIP-sequencing kits
- RNA sequencing kits
- whole genomic amplification kits
- 5-hmC and 5-mC analysis kits
- Others
- Reagents
- Antibodies
- Buffers
- Histones
- Magnetic beads
- Primers
- Others
Application
- Oncology
- Metabolic Diseases
- Developmental Biology
- Immunology
- Cardiovascular Diseases
- Others
Technology
- DNA Methylation
- Histone Methylation
- Others
End User
- Academic and Research Institutes
- Pharmaceutical Companies and Biotechnology Companies
- Contract Research Organizations (CROs)
Global Epigenetics Market Regional Analysis/Insights
The global epigenetics market is analyzed and market size insights and trends are provided by country, product, application, technology, and end user as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate the global epigenetics market due to the growing research activities on epigenetics. Furthermore, the presence of innovative healthcare amenities that are provided and continuous developments in the diagnostic process are expected to further boost market growth in the region during the forecast period.
Asia-Pacific is expected to be the fastest-growing region in the market due to the rise in disposable income. Moreover, the growing untapped clinical needs of the patients are further expected to drive market growth in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global epigenetics market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2011-2021.
Competitive Landscape and Global Epigenetics Market Share Analysis
The global epigenetics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global epigenetics market are:
- Bio-Techne. (U.S.)
- Promega Corporation (U.S.)
- GeneTex, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Eisai Co., Ltd. (Japan)
- Novartis AG (Switzerland)
- Abcam plc (U.K.)
- Diagenode s.a. (U.S.)
- Active Motif, Inc. (U.S.)
- Zymo Research Corporation. (U.S.)
- Thermo Fisher Scientific (U.S.)
- Cellcentric (Germany)
- Syndax (U.S.)
- New England Biolabs (U.S.)
- Epizyme, Inc. (U.S.)
- Domainex (U.K.)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- AsisChem Inc. (U.S.)
- Enzo Life Sciences, Inc. (U.S.)
- EpiGentek Group Inc. (U.S.)
- BioVision Inc. (U.S.)
SKU-